美托洛尔联合左旋卡尼汀治疗慢性心力衰竭患者的临床疗效及对心功能、心肌重塑的影响

Clinical efficacy of metoprolol combined with levocarnitine in the treatment of patients with chronic heart failure and its effect on cardiac function and myocardial remodeling

目的探究美托洛尔联合左旋卡尼汀治疗慢性心力衰竭患者的临床疗效及对心功能、心肌重塑的影响。方法选取2018年5月至2020年5月本院收治的慢性心力衰竭患者124例作为研究对象,随机分为观察组与对照组,每组62例。两组均接受常规慢性心力衰竭治疗,对照组在常规治疗基础上采用美托洛尔治疗,观察组在对照组基础上联合左旋卡尼汀治疗,比较两组心功能指标、心肌重塑情况及药物不良反应发生率。结果治疗后,观察组LVESV、LVEDV均明显低于对照组,LVEF明显高于对照组(P<0.05)。治疗前,两组心率和6 min步行距离比较差异无统计学意义;治疗后,观察组心率明显低于对照组,6 min步行距离明显长于对照组(P<0.05)。观察组不良反应发生率为1.61%,明显低于对照组的16.13%,差异有统计学意义(P<0.05)。结论美托洛尔联合左旋卡尼汀治疗慢性心力衰竭效果显著,不仅能有效改善患者心功能,促进患者恢复,抑制心肌重塑,且能有效降低并发症发生率,值得临床推广应用。

Objective To explore the clinical efficacy of metoprolol combined with levocarnitine in the treatment of chronic heart failure patients and its effect on cardiac function and myocardial remodeling.Methods 124 patients with chronic heart failure admitted to our hospital from May2018 to May 2020 were selected as the research subjects,and randomly divided into observation group and control group,with 62 cases in each group.Both groups received conventional treatment of chronic heart failure,the control group was treated with metoprolol on the basis of conventional treatment,and the observation group was treated with levocarnitine on the basis of the control group.The cardiac function indexes,myocardial remodeling and the incidence of adverse drug reactions were compared between the two groups.Results After treatment,LVESV and LVEDV in the observation group were significantly lower than those in the control group,and LVEF was significantly higher than that in the control group(P<0.05).Before treatment,there was no significant difference in heart rate and 6 min walking distance between the two groups.After treatment,the heart rate of the observation group was significantly lower than that of the control group,and the 6 min walking distance of the observation group was significantly longer than that of the control group(P<0.05).The incidence of adverse reactions in the observation group was 1.61%,which was significantly lower than 16.13%in the control group,and the difference was statistically significant(P<0.05).Conclusion Metolol combined with levocarnitine in the treatment of chronic heart failure has significant effect,can not only effectively improve the cardiac function of patients,promote the recovery of patients,inhibit myocardial remodeling,but also can effectively reduce the incidence of complications,it is worthy of clinical application.